title: Recent trends in product development and regulatory issues on impurities in active pharmaceutical ingredient (API) and drug products. Part 1: Predicting degradation related impurities and impurity considerations for pharmaceutical dosage forms.
authors.affiliation: Pfizer Global Research and Development, Groton, Connecticut, USA.
authors.forename: Karen M
authors.initials: KM
authors.lastname: Alsante
authors.forename: Kim
authors.initials: K
authors.lastname: Huynh-Ba
authors.forename: Steven W
authors.initials: SW
authors.lastname: Baertschi
authors.forename: Robert A
authors.initials: RA
authors.lastname: Reed
authors.forename: Margaret S
authors.initials: MS
authors.lastname: Landis
authors.forename: Mark H
authors.initials: MH
authors.lastname: Kleinman
authors.forename: Christopher
authors.initials: C
authors.lastname: Foti
authors.forename: Venkatramana M
authors.initials: VM
authors.lastname: Rao
authors.forename: Paul
authors.initials: P
authors.lastname: Meers
authors.forename: Andreas
authors.initials: A
authors.lastname: Abend
authors.forename: Daniel W
authors.initials: DW
authors.lastname: Reynolds
authors.forename: Biren K
authors.initials: BK
authors.lastname: Joshi
mesh_terms: D004304:Dosage Forms; D004340:Drug Contamination; D055808:Drug Discovery / Q000379:methods*
chemical_list: D004304:Dosage Forms